Juliette Lambert

Le Chesnay, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia

Published: April 14, 2026

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Journal: Blood cancer journal

Published: March 10, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Multicenter Analysis of General presentations and Imaging features in Cerebral MUCORmycosis (MAGICMUCOR): toward different entities.

Multicenter Analysis of General presentations and Imaging features in Cerebral MUCORmycosis (MAGICMUCOR): toward different entities.

Journal: Medical mycology

Published: October 10, 2025

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Journal: Leukemia

Published: August 25, 2025

Rare case of PLAG1::RUNX1 fusion mimicking classical t(8;21): the value of optical genome mapping in acute myeloid leukemia.

Rare case of PLAG1::RUNX1 fusion mimicking classical t(8;21): the value of optical genome mapping in acute myeloid leukemia.

Journal: Molecular cytogenetics

Published: June 16, 2025

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Blood advances

Published: March 28, 2025

Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review

Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review

Journal: Annales de biologie clinique

Published: August 16, 2024

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.

Journal: Blood cancer journal

Published: April 03, 2024

Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy

Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy

Journal: Bulletin du cancer

Published: December 27, 2023

The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia.

The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia.

Journal: The FEBS journal

Published: October 20, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026